BLA 020986 · Novo Nordisk INC
Novolog Penfill
Insulin Aspart Recombinant · Subcutaneous · Insulin Analog
NovelLast checked: Nov 20, 2026Latest source record: Feb 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jun 7, 2000
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
8
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Aspart Recombinant" as an intervention, any sponsor and status, largest first.
- CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)Pivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01848990 · 456 participants · Start Mar 2013 · Primary completion Feb 2014
Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Precommercial Hylenex recombinant (hyaluronidase human injection) and 3 more · For: Type 1 Diabetes Mellitus
Sites: Concord, California; Encino, California; Escondido, California · 39 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194245 · 135 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; recombinant human hyaluronidase PH20 and 3 more · For: Diabetes Mellitus, Type 1
Sites: Escondido, California; La Jolla, California; San Mateo, California · 19 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194258 · 132 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; Insulin aspart and 3 more · For: Diabetes Mellitus, Type II
Sites: Concord, California; Encino, California; Escondido, California · 22 sites in all
Biocon LimitedIndustry
NCT04141423 · 55 participants · Start Oct 28, 2019 · Primary completion Apr 23, 2021
Drug: Tregopil · For: Type 1 Diabetes Mellitus (T1DM)
Sites: Mainz, Germany
Halozyme TherapeuticsIndustry
NCT01275131 · 45 participants · Start Jan 2011 · Primary completion Dec 2011
Drug: Insulin aspart; Recombinant human hyaluronidase PH20 (rHuPH20) · For: Type 1 Diabetes Mellitus
Sites: Chula Vista, California
Halozyme TherapeuticsIndustry
NCT01526733 · 25 participants · Start Dec 2011 · Primary completion Aug 2012
Drug: Sham Injection; Recombinant human hyaluronidase PH20 and 2 more · For: Type 1 Diabetes Mellitus
Sites: Chula Vista, California
Nastech Pharmaceutical Company, Inc.Industry
NCT00624767 · 18 participants · Start Mar 2008 · Primary completion Apr 2008
Drug: Insulin (recombinant human insulin); NovoLog · For: Diabetes Mellitus
Sites: San Antonio, Texas
Halozyme TherapeuticsIndustry
NCT00979875 · 14 participants · Start Sep 2009 · Primary completion Feb 2010
Drug: Recombinant human hyaluronidase PH20 (rHuPH20); Insulin lispro and 2 more · For: Healthy
Sites: Chula Vista, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Novolog (Insulin Aspart)
2024 spending
$85.5M
Beneficiaries
111,329
370,385 claims
Per beneficiary
$768
$6.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $586,977,753 |
| 2021 | $546,397,744 |
| 2022 | $522,823,749 |
| 2023 | $518,394,273 |
| 2024 | $85,508,606 |
Part D: Novolog Flexpen (Insulin Aspart)
2024 spending
$319M
Beneficiaries
479,549
1,483,591 claims
Per beneficiary
$665
$8.90 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,844,084,368 |
| 2021 | $1,817,675,039 |
| 2022 | $1,839,750,389 |
| 2023 | $1,875,605,627 |
| 2024 | $318,913,549 |
Part D: Novolog Penfill (Insulin Aspart)
2024 spending
$2.2M
Beneficiaries
3,863
9,358 claims
Per beneficiary
$578
$8.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,204,522 |
| 2021 | $9,825,961 |
| 2022 | $11,977,767 |
| 2023 | $13,098,434 |
| 2024 | $2,231,024 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Novo Nordisk · Also marketed as Novolog Flextouch, Novolog Flexpen, Novolog, Novolog Innolet
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.